Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | DDT | P30046 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CD74 | P04233 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28433847 | 0.82 | KMT2A (0.46) | ALDH1A1MAPTLMNA | |
| SCHEMBL28669741 | 0.81 | ALDH1A1 (0.64) | KMOERN1TP53CASP6PTGER1 | |
| SCHEMBL20189898 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPT | |
| SCHEMBL29973546 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPT | |
| SCHEMBL1936226 | 0.81 | ROCK2 (0.52) | ALDH1A1ROCK2MAPT | |
| SCHEMBL1018931 | 0.77 | KMO (0.60) | KMODDTPTGER1CYP3A4CYP2C9 | |
| SCHEMBL26969164 | 0.77 | PTAFR (0.47) | ERN1CYP3A4CYP2C9ALDH1A1ROCK2 | |
| SCHEMBL408308 | 0.76 | ERN1 (0.59) | KMOERN1TP53CASP6ALDH1A1 | |
| SCHEMBL31415060 | 0.76 | ERN1 (0.59) | KMOERN1TP53CASP6ALDH1A1 | |
| SCHEMBL17461846 | 0.76 | CASP6 (0.53) | ERN1TP53CASP6ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416815-A1 | METHOD FOR LABELING NUCLEIC ACID | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-12-28 | — | — | US | disclosed |
| EP-4211262-A1 | METHOD FOR LABELING NUCLEIC ACID | Cambridge Enterprise Limited (GB) | 2023-07-19 | — | — | EP | disclosed |
| CN-116323603-A | Method for labeling nucleic acids | 剑桥实业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022053718-A1 | METHOD FOR LABELING NUCLEIC ACID | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-03-17 | — | — | WO | disclosed |
| EP-2331502-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2331502-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2545050-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-13 | — | — | EP | disclosed |
| CN-102209711-B | Compounds for the treatment of hepatitis C | BRISTOL MYERS SQUIBB CO | 2014-06-18 | — | — | CN | disclosed |
| CN-103864783-A | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO | 2014-06-18 | — | — | CN | disclosed |
| US-8536338-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2011112186-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2331502-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| WO-2010030538-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030538-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416815-A1 | METHOD FOR LABELING NUCLEIC ACID | ALKBH1, ALKBH2, NT5C3B | KMO 1173/4885ERN1 1348/4885TP53 1342/4885 |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KMO 4328/4885ERN1 718/4885TP53 299/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KMO 4328/4885ERN1 718/4885TP53 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.